Comparative analysis of oncogenic properties and nuclear factor-kB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes

Haematologica

Volumn 94, Issue 3, 2009, Pages 355-363

  Faumont, Nathalie ^a,b,c   Chanut, Aurélie ^c   Benard, Alan ^a,b   Cogne, Nadine ^a,b   Delsol, Georges ^a,b   Feuillard, Jean ^a,c,d   Meggetto, Fabienne ^a,b  

^a Université Paul Sabatier   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Centre National de la Recherche Sclentlflque   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Epstein barr virus; Hodgkin's lymphoma; LMP1; Nf b; Oncogenic potential

Indexed keywords

GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; RECOMBINANT INTERLEUKIN 3;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BENIGN TUMOR; CARCINOGENICITY; CELL CULTURE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLONOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC TRANSFECTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPH NODE; MOUSE; MUTATION RATE; NONHUMAN; PROTEIN VARIANT; REED STERNBERG CELL;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BASE SEQUENCE; CELL LINE; DNA MUTATIONAL ANALYSIS; GENETIC VARIATION; HODGKIN DISEASE; HUMANS; IMMUNOBLOTTING; LUCIFERASES, RENILLA; MOLECULAR SEQUENCE DATA; MUTATION; NF-KAPPA B; ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; REED-STERNBERG CELLS; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 63149196730     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13269     Document Type: Article

References (44)

1. Thorley-Lawson DA. EBV the prototypical human tumor virus-just how bad is it?- J Allergy Clin Immunol 2005;116:251-61.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat RevCancer 2004;4:757-68.
3. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lympho-cyte growth transformation. ProcNatl Acad Sci USA 1993;90:9150-4.
4. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V,Raab-Traub N. Expression of theEpstein-Barr virus latent membraneprotein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad SciUSA 1998;95:11963-8.
5. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a consti- tutively active receptor molecule.Embo J 1997;16:6131-40.
6. d, Erickson KD, Hoedt-Miller M, Martin JM. The cytoplasmic amino-terminus of the latentmembrane protein-1 of Epstein-Barrvirus: relationship between transmembrane orientation and effectorfunctions of the carboxy-terminusand transmembrane domain. Oncogene 2001;20:5313-30.
7. Huen DS, Henderson SA, CroomCarter D, Rowe M. The Epstein-Barrvirus latent membrane protein-1(LMP1) mediates activation of NF-kappa B and cell surface phenotypevia two effector regions in its carboxy-terminal cytoplasmic domain.Oncogene 1995;10:549-60.
8. Dawson CW, Tramountanis G,Eliopoulos AG, Young LS. EpsteinBarr virus latent membrane protein 1(LMP1) activates the phosphatidyl-inositol 3-kinase/Akt pathway topromote cell survival and induceactin filament remodeling. J Biol Chem 2003;278:3694-704.
9. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS.Activation of the p38 mitogen-acti-vated protein kinase pathway byEpstein-Barr virus-encoded latentmembrane protein 1 coregulatesinterleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-96.
10. Kieser A, Kilger E, Gires O, UeffingM, Kolch W, Hammerschmidt W.Epstein-Barr virus latent membraneprotein-1 triggers AP-1 activity viathe c-Jun N-terminal kinase cascade.Embo J 1997;16:6478-85.
11. oody CA, Scott RS, Su T, SixbeyJW. Length of Epstein-Barr virus termini as a determinant of epithelialcell clonal emergence. J Virol 2003;77:8555-61.
12. Rowe M, Young LS, Cadwallader K,Petti L, Kieff E, Rickinson AB.Distinction between Epstein-Barrvirus type A (EBNA 2A) and type B(EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. JVirol 1989;63:1031-9.
13. Miller WE, Edwards RH, WallingDM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 1994;75:2729-40.
14. Walling DM, Shebib N, Weaver SC,Nichols CM, Flaitz CM, Webster-Cyriaque J. The molecular epidemiology and evolution of Epstein-Barrvirus: sequence variation and geneticrecombination in the latent membrane protein-1 gene. J Infect Dis1999;179:763-74.
15. Srivastava G, Wong KY, Chiang AK, Lam KY, Tao Q. Coinfection of multiple strains of Epstein-Barr virus inimmunocompetent normal individuals: reassessment of the viral carrier state. Blood 2000;95:2443-5.
16. 16.Brousset P, Schlaifer D, Meggetto F,Bachmann E, Rothenberger S, Pris J,et al. Persistence of the same viralstrain in early and late relapses ofEpstein-Barrvirus-associatedHodgkin's disease. Blood 1994;84:2447-51.
17. Faumont N, Al Saati T, Brousset P,Offer C, Delsol G, Meggetto F.Demonstration by single-cell PCRthat Reed-Sternberg cells and bystander B lymphocytes are infected by different Epstein-Barr virusstrains in Hodgkin's disease. J GenVirol 2001;82:1169-74.
18. Faumont N, Trempat P, Brousset P,Delsol G, Meggetto F. In Hodgkin'sdisease Reed-Sternberg cells and normal B-lymphocytes are infected byrelated Epstein-Barr virus strains.Virus Res 2004;101:163-73.
19. Miller G, Shope T, Lisco H, Stitt D,Lipman M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkeyand marmoset leukocytes. Proc NatlAcad Sci USA 1972;69:383-7.
20. Meggetto F, Muller C, Henry S,Selves J, Mariame B, Brousset P, et al.Epstein-Barr virus (EBV)-associatedlymphoproliferations in severe combined immunodeficient mice transplanted with Hodgkin's diseaselymph nodes: implications of EBV-positive bystander B lymphocytesrather than EBV-infected ReedSternberg cells. Blood 1996;87:243542.
21. Palacios R, Steinmetz M. Independent mouse clones thatexpress B-220 surface antigen contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985;41:727-34.
22. Rothenberger S, Bachmann E,Berger C, McQuain C, Odermatt BE,Knecht H. Natural 30 base pair and69 base pair deletion variants of theLMP1 oncogene do stimulate NFkappaB-mediated transcription.Oncogene 1997;14:2123-6.
23. Nagamine M, Takahara M, KishibeK, Nagato T, Ishii H, Bandoh N, etal. Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes 2007; 34:47-54.
24. Edwards RH, Sitki-Green D, MooreDT, Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 2004; 78:868-81.
25. Adam M, Pogacic V, Bendit M,Chappuis R, Nawijn MC, Duyster J,et al. Targeting PIM kinases impairssurvival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant formsof Ems-like tyrosine kinase 3 andBCR/ABL. Cancer Res 2006;66:3828-35.
26. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoprolifera- tive disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17:5321-33.
27. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc trans activation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997;94:6658-63.
28. Bargou RC, Emmerich F, Krapp- mann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
29. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCu- brey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189-218.
30. Shishodia S, Aggarwal BB. Nuclear factor-kappaB: a friend or a foe in cancerf- Biochem Pharmacol 2004; 68:1071-80.
31. Hu LF, Zabarovsky ER, Chen F Cao SL, Ernberg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72:2399-409.
32. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8:1575-83.
33. Trivedi P, Hu LF, Chen F, Christensson B, Masucci MG, Klein G, et al. Epstein-Barr virus (EBV)- encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell- derived homologue. Eur J Cancer 1994;30A:84-8.
34. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82: 2937-42.
35. Sandvej K, Peh SC, Andresen BS, Pallesen G. Identification of potential hot spots in the carboxy-termi- nal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 1994;84:4053-60.
36. hou XG, Sandvej K, Li PJ, Ji XL, Yan QH, Zhang XP, et al. Epstein- Barr virus gene polymorphisms in Chinese Hodgkin's disease cases and healthy donors: identification of three distinct virus variants. J Gen Virol 2001;82(Pt 5):1157-67.
37. rug LT, Moser JM, Dickerson SM, Speck SH. Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathogens 2007;3:ell.
38. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006;80:6458- 68.
39. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 1999;18:6959-64.
40. He Z, Xin B, Yang X, Chan C, Cao L. Nuclear factor-kappaB activation is involved in LMP1 -mediated transformation and tumorigenesis of rat- 1 fibroblasts. Cancer Res 2000;60: 1845-8.
41. Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 2001;282:278-87.
42. Soni V, Yasui T, Cahir-McFarland E, Kieff E. LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB. J Virol 2006;80:10787-93.
43. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006;118:1853-61.
44. Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma. Blood 2006;108:1013- 20.